Phaseline

Companies › Five Eleven Pharma

Five Eleven Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ga-68 P16-093
PSMA-targeted PET imaging agent (gallium-68 labeled PSMA ligand)
FOLH1Phase 1Prostate Cancer Recurrent–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03444844Ga-68 P16-093Phase 1Prostate Cancer RecurrentOncologyOct 2020

Targets

FOLH1 (1)

Companies with the same targets

Novartis Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Clarity Pharmaceuticals Convergent Therapeutics Fusion Pharmaceuticals T.O.A.D. Oncology VitsGen Therapeutics Endocyte AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.